Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 24 | 2024 | 156 | 3.580 |
Why?
|
| Antiparkinson Agents | 8 | 2024 | 26 | 1.220 |
Why?
|
| Deep Brain Stimulation | 8 | 2022 | 42 | 1.080 |
Why?
|
| Levodopa | 6 | 2024 | 47 | 0.920 |
Why?
|
| Chorea | 3 | 2023 | 13 | 0.890 |
Why?
|
| Huntington Disease | 3 | 2023 | 24 | 0.890 |
Why?
|
| Essential Tremor | 5 | 2026 | 10 | 0.770 |
Why?
|
| Double-Blind Method | 14 | 2024 | 729 | 0.690 |
Why?
|
| Carbidopa | 3 | 2024 | 6 | 0.650 |
Why?
|
| Antipsychotic Agents | 3 | 2023 | 233 | 0.600 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 81 | 0.440 |
Why?
|
| Treatment Outcome | 16 | 2026 | 5595 | 0.440 |
Why?
|
| Neuroprotective Agents | 1 | 2015 | 101 | 0.430 |
Why?
|
| Dyskinesias | 1 | 2024 | 4 | 0.420 |
Why?
|
| Globus Pallidus | 3 | 2019 | 8 | 0.410 |
Why?
|
| Subthalamic Nucleus | 3 | 2019 | 12 | 0.400 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 2 | 2026 | 11 | 0.390 |
Why?
|
| Anesthesia, General | 3 | 2018 | 99 | 0.360 |
Why?
|
| Creatine | 3 | 2017 | 39 | 0.350 |
Why?
|
| Indans | 2 | 2023 | 7 | 0.320 |
Why?
|
| Tetrabenazine | 3 | 2023 | 14 | 0.320 |
Why?
|
| Severity of Illness Index | 9 | 2026 | 1049 | 0.310 |
Why?
|
| Aged | 22 | 2026 | 10429 | 0.310 |
Why?
|
| Wakefulness | 3 | 2018 | 47 | 0.300 |
Why?
|
| Humans | 36 | 2026 | 53230 | 0.270 |
Why?
|
| Male | 27 | 2026 | 27435 | 0.270 |
Why?
|
| Neurosurgical Procedures | 4 | 2019 | 137 | 0.270 |
Why?
|
| Female | 27 | 2026 | 28782 | 0.260 |
Why?
|
| Middle Aged | 20 | 2026 | 13419 | 0.250 |
Why?
|
| House Calls | 2 | 2017 | 26 | 0.250 |
Why?
|
| Stereotaxic Techniques | 4 | 2021 | 41 | 0.250 |
Why?
|
| Fingers | 3 | 2017 | 34 | 0.240 |
Why?
|
| Dopamine Agents | 2 | 2014 | 13 | 0.220 |
Why?
|
| Activities of Daily Living | 3 | 2026 | 186 | 0.220 |
Why?
|
| Tremor | 2 | 2013 | 11 | 0.200 |
Why?
|
| Aged, 80 and over | 10 | 2026 | 3494 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 1180 | 0.180 |
Why?
|
| Delayed-Action Preparations | 2 | 2023 | 58 | 0.170 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 275 | 0.170 |
Why?
|
| Drug Combinations | 2 | 2023 | 138 | 0.170 |
Why?
|
| Median Nerve | 1 | 2020 | 4 | 0.170 |
Why?
|
| Radial Nerve | 1 | 2020 | 3 | 0.170 |
Why?
|
| Electric Stimulation Therapy | 1 | 2020 | 23 | 0.160 |
Why?
|
| Hand | 1 | 2020 | 50 | 0.160 |
Why?
|
| Brain Mapping | 1 | 2021 | 223 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2021 | 1583 | 0.160 |
Why?
|
| Movement Disorders | 1 | 2019 | 17 | 0.150 |
Why?
|
| Monitoring, Ambulatory | 1 | 2019 | 9 | 0.150 |
Why?
|
| Actigraphy | 1 | 2019 | 24 | 0.150 |
Why?
|
| Peripheral Nerves | 1 | 2019 | 43 | 0.140 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 370 | 0.140 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2015 | 54 | 0.140 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2017 | 10 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 47 | 0.130 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2016 | 14 | 0.120 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2016 | 23 | 0.120 |
Why?
|
| Lung | 1 | 2019 | 481 | 0.120 |
Why?
|
| Videoconferencing | 1 | 2016 | 38 | 0.120 |
Why?
|
| Remote Consultation | 1 | 2016 | 30 | 0.120 |
Why?
|
| Dementia | 1 | 2017 | 141 | 0.120 |
Why?
|
| Selegiline | 1 | 2015 | 5 | 0.120 |
Why?
|
| Medical Futility | 1 | 2015 | 8 | 0.120 |
Why?
|
| Adult | 9 | 2023 | 14534 | 0.120 |
Why?
|
| Dopamine Agonists | 1 | 2014 | 10 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2016 | 456 | 0.110 |
Why?
|
| Infusions, Subcutaneous | 1 | 2024 | 2 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 405 | 0.100 |
Why?
|
| Serotonin 5-HT2 Receptor Agonists | 1 | 2013 | 5 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 145 | 0.100 |
Why?
|
| Disease Progression | 1 | 2017 | 880 | 0.100 |
Why?
|
| Urea | 1 | 2013 | 80 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2017 | 338 | 0.100 |
Why?
|
| Electrodes, Implanted | 3 | 2021 | 36 | 0.100 |
Why?
|
| Prospective Studies | 4 | 2021 | 2411 | 0.100 |
Why?
|
| Piperidines | 1 | 2013 | 98 | 0.100 |
Why?
|
| Brain | 1 | 2021 | 1350 | 0.100 |
Why?
|
| Sensation Disorders | 1 | 2012 | 11 | 0.090 |
Why?
|
| Psychotic Disorders | 1 | 2013 | 138 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2026 | 6819 | 0.090 |
Why?
|
| Postural Balance | 1 | 2012 | 59 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 774 | 0.090 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2012 | 38 | 0.090 |
Why?
|
| Telemedicine | 1 | 2017 | 512 | 0.080 |
Why?
|
| Accidental Falls | 1 | 2012 | 107 | 0.080 |
Why?
|
| Quality of Life | 3 | 2018 | 902 | 0.070 |
Why?
|
| Canada | 2 | 2014 | 112 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 198 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2318 | 0.070 |
Why?
|
| Myasthenia Gravis | 1 | 2008 | 18 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 146 | 0.060 |
Why?
|
| Time Factors | 3 | 2017 | 2991 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2017 | 411 | 0.060 |
Why?
|
| Physicians | 2 | 2019 | 242 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2017 | 345 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2023 | 6 | 0.050 |
Why?
|
| Research | 1 | 2023 | 109 | 0.050 |
Why?
|
| Animals | 1 | 2016 | 13526 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4511 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 89 | 0.040 |
Why?
|
| Microelectrodes | 1 | 2019 | 17 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2019 | 84 | 0.040 |
Why?
|
| Wrist | 1 | 2019 | 15 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 182 | 0.040 |
Why?
|
| United States | 2 | 2014 | 5409 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2016 | 21 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2016 | 52 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2019 | 384 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 189 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 292 | 0.030 |
Why?
|
| Hypotension, Orthostatic | 1 | 2014 | 3 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 247 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2014 | 114 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 169 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Sleep | 1 | 2015 | 195 | 0.030 |
Why?
|
| Proprioception | 1 | 2013 | 7 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2015 | 204 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1557 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 265 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 373 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 623 | 0.030 |
Why?
|
| Meningioma | 1 | 2013 | 48 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 126 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 547 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 747 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2012 | 92 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 630 | 0.020 |
Why?
|
| Walking | 1 | 2012 | 106 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1219 | 0.020 |
Why?
|
| Receptors, Cholinergic | 1 | 2008 | 14 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 147 | 0.020 |
Why?
|